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Q4DV70 is annotated in the Trypanosoma cruzi CL Brener genome as a
hypothetical protein with a predicted thioredoxin-like fold, although the
catalytic cysteine residues that are conserved in typical oxidoreductases are
replaced by serine residues. Gene-expression analysis indicates that this protein
is differentially expressed during the T. cruzi life cycle, suggesting that it plays an
important role during T. cruzi development. The gene coding for Q4DV70 was
cloned and the protein was overexpressed in Escherichia coli with an N-terminal
His tag. Purification of Q4DV70 was carried out by affinity and size-exclusion
chromatography and the His tag was removed by TEV protease digestion.
Crystals of Q4DV70 were grown using the sitting-drop vapour-diffusion method.
A diffraction data set was collected to 1.50 Å resolution from a single crystal
grown in 25% PEG 1500, 200 mM sodium thiocyanate pH 6.9, 10 mM phenol
and 10% ethylene glycol. The crystal belonged to space group P212121, with unit-
cell parameters a = 35.04, b = 50.32, c = 61.18 Å. The Q4DV70 structure was
solved by molecular replacement using protein disulfide isomerase from yeast
(PDB code 2b5e) as a search model. Initial refinement of the model indicated
that the solution was correct. These data are being used for refinement of the
model of Q4DV70.
1. Introduction
Chagas disease is caused by the protozoan Trypanosoma cruzi
(Chagas, 1909) and affects more than 7.7 million people in Latin
America. The pathogen’s life cycle is complex, involving a mamma-
lian and a triatomine insect host and at least three developmental
stages: epimastigotes, trypomastigotes and amastigotes (De Souza,
1984). Metacyclogenesis is the transformation from the replicative
stage present in the insect gut (the epimastigotes) to the infective
stage (the metacyclic trypomastigotes) (De Souza, 1984). Transition
from stages during metacyclogenesis is controlled by the activation of
specific genes. In trypanosomatids, gene expression is mostly regu-
lated by post-transcriptional mechanisms (Avila et al., 2003; Minning
et al., 2003; Haile & Papadopoulou, 2007; Clayton & Shapira, 2007)
and analysis of the level of mRNAs associated with polysomes gives a
consistent signature of the genes that are being translated in each
stage. Global analysis using DNA microarray indicated that the
mRNA encoding Q4DV70 (XP_818273) shows differential associa-
tion with polysomes during the T. cruzi life cycle (Krieger & Gold-
enberg, unpublished results). mRNAs whose levels of association
with polysomes correlate to a single developmental stage are thought
to play important functions during metacyclogenesis, in contrast to
mRNAs encoding housekeeping proteins, which have similar asso-
ciation with polysomes at all stages.
Although the Q4DV70 protein has been annotated as a conserved
hypothetical protein in the T. cruzi CL Brener genome, its fold can be
predicted to be thioredoxin-like owing to sequence similarity. This
fold is composed of a four-stranded -sheet flanked by three -helices
and usually contains a CXXC motif in the active site (Martin, 1995).
The thioredoxin fold was named after the Escherichia coli thio-
redoxin structure, which was the first protein structure of this family
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to be determined (Holmgren et al., 1975). It is found in a large
number of proteins such as thioredoxins (Holmgren et al., 1975),
glutharedoxins (Sodano et al., 1991), glutathione S-transferases
(Reinemer et al., 1991), DsbA (Martin et al., 1993), glutathione
peroxidases (Epp et al., 1983) and protein disulfide isomerases (PDIs;
Kemmink et al., 1996). The sequence-identity levels between proteins
from these groups are very low and do not suggest structural simi-
larity. Furthermore, the groups do not share the same biological
functions. Indeed, although Q4DV70 has a thioredoxin-like fold, it
does not contain any cysteines in its sequence, rendering it incapable
of acting as an oxidoreductase. However, proteins of this family have
also been reported to display chaperone activity that is independent
of the formation and/or isomerization of disulfides. Thioredoxin from
E. coli promoted the functional folding of bacterial galactose
receptor, a protein without any cysteines (Kern et al., 2003). PDI,
DsbA and DsbC assisted the refolding of d-glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), a protein that lacks disulfides (Cai
et al., 1994; Zheng et al., 1997; Chen et al., 1999).
Q4DV70 possesses a 30-residue signal peptide in the N-terminal
region according to theoretical predictions (SignalP 3.0 server;
Emanuelsson et al., 2007), indicating that it is transported to the
endoplasmic reticulum. There, Q4DV70 may have a chaperone
activity independent of oxidoreductase activity towards nascent
polypeptide chains, preventing them from aggregating and main-
taining them in a favourable conformation for correct folding, similar
to other proteins with a thioredoxin-like fold. In this work, we
describe the crystallization and solution of the T. cruzi Q4DV70
structure, which should help in understanding its molecular function
and possible thioredoxin-like chaperone activity.
2. Materials and methods
2.1. Production and purification of recombinant Q4DV70
The Q4DV70 coding sequence, starting from amino acid 30 in
order to exclude the signal peptide, was amplified by PCR from
T. cruzi Dm28c genomic DNA using the following oligonucleotides as
primers: Q4DV70F, 50-CTG ACA TAT GGC GTC AAA TGT GGC
AAA TGA C-30, and Q4DV70R, 50-TCA GAT CTT CAT GTG TTC
TGA AAA ACA AAA CTG-30. The resulting DNA fragment was
cloned into the NdeI and BamHI restriction sites of plasmid pET-
TEV (Carneiro et al., 2006) to produce pET-TEV/Q4DV70. DNA
sequencing of Q4DV70 amplified using DNA from the Dm28c strain
as a template revealed a difference from the sequence deposited in
the database for the CL Brener strain. In the Dm28c strain Tyr94 is
replaced by a histidine. This can be explained by the genetic varia-
bility between these two T. cruzi strains.
Escherichia coli BL21(DE3)slyD competent cells were trans-
formed with pET-TEV/Q4DV70. A fresh single colony was grown in
10 ml Luria–Bertani medium (LB) containing 50 mg ml1 kanamycin
for 16 h (200 rev min1 and 310 K). This culture was inoculated into
1 l fresh LB with kanamycin, maintained under the same conditions
and induced with 1 mM isopropyl -d-1-thiogalactopyranoside when
the culture reached an optical density of 0.8 at 600 nm. Following a
4 h induction, the cells were harvested (6000g, 15 min, 277 K) and the
pellet was suspended in 10 ml buffer A (50 mM sodium phosphate pH
7.4, 100 mM NaCl, 5% glycerol) containing 1 mM phenylmethane-
sulfonylfluoride (PMSF). Cell lysis was performed by lysozyme
treatment (80 mg ml1 for 1 h at 277 K) and sonication. The lysates
were clarified by centrifugation (20 000g, 30 min, 277 K) and sub-
mitted to chromatography using a 5 ml HiTrap Chelating HP (GE
Healthcare) column coupled to an ÄKTA FPLC (GE Healthcare)
system with a flow rate of 1 ml min1. The column was washed with
15 column volumes (CV) of buffer A and eluted with a step gradient
of buffer A containing 0–500 mM imidazole as follows: 0–100 mM in
5 CV, 100–300 mM in 25 CV and 300–500 mM in 2 CV.
Subsequently, the His tag was digested in a reaction mixture
containing 0.26 mg ml1 Q4DV70, 0.013 mg ml1 TEV protease,
50 mM Tris–HCl pH 8.0, 0.5 mM ethylenediaminetetraacetic acid
(EDTA) and 1 mM dithiothreitol (DTT) for 15 h at room tempera-
ture. The reaction was stopped with 0.01% sodium dodecyl sulfate
(SDS) and applied onto a Superdex 75 16/60 column (GE Health-
care) equilibrated with 50 mM sodium phosphate pH 7.4, 100 mM
NaCl and 5% glycerol. This chromatography was carried out on an
ÄKTA FPLC (GE Healthcare) system with a 1 ml min1 flow rate. A
second affinity chromatography step was carried out to adsorb the
His-tagged TEV protease and the residual fraction of undigested
Q4DV70. This chromatography was carried out on a 5 ml HiTrap
Chelating HP (GE Healthcare) column as described above. The
flowthrough of this column containing Q4DV70 without the His tag
was dialyzed against 20 mM Tris–HCl pH 8.0, 100 mM NaCl, 5%
glycerol, concentrated by ultrafiltration and used in crystallization
assays.
2.2. Crystallization, data collection and processing
Crystallization was carried out by vapour diffusion using a
HoneyBee 963 Robot (Genomic Solutions). Sitting drops containing
200 nl of either 3 or 6 mg ml1 Q4DV70 and 200 nl reservoir solution
were equilibrated against 80 ml reservoir solution at 291 K. The
following crystallization screens were tested: a sparse-matrix screen
from the Joint Center for Structural Genomics (JCSG; Page et al.,
2003), the PACT Suite for a systematic analysis of the effects of pH,
anions and cations (Newman et al., 2005), precipitant synergy
(Majeed et al., 2003), Wizard Screens I and II (Hol et al., 2001),
SaltRx (Gilliland et al., 1994; Kanaujia et al., 2007) and Crystal Screen
and Crystal Screen 2 from Hampton Research (Jancarik & Kim,
1991). Initially, needle-type crystals were obtained using 20% PEG
3350, 200 mM sodium thiocyanate pH 6.9 as precipitant. Crystal
optimization was performed by changing the concentrations of
thiocyanate and PEG and the PEG molecular mass. Sitting drops
containing 1 ml Q4DV70 and 1 ml reservoir solution were equilibrated
against 80 ml reservoir solution. A second round of optimization was
carried out with additive screens (Additive Screens I, II and III;
Hampton Research) in the optimized condition (25% PEG 1500,
200 mM sodium thiocyanate pH 6.9) using hanging drops containing
2.5 ml Q4DV70, 2.0 ml reservoir solution and 0.5 ml additive solution
equilibrated against 200 ml reservoir solution. The best crystals were
grown using 10 mM phenol as an additive and 10%(v/v) ethylene-
glycol for cryoprotection.
X-ray diffraction data were collected on the W01B-MX2 beamline
of the Brazilian Synchrotron Light Laboratory (LNLS), Campinas,
Brazil using a MAR 225 CCD detector (MAR Research). Crystals
were retrieved from the drops with cryoloops and mounted on the
goniometer; a nitrogen-gas stream at 100 K was used for flash-
cooling. The first data set contained 360 images and the second
contained 129 images; both used an oscillation of 1. The wavelength
of the X-rays was 1.459 Å. Data processing was performed with the
HKL-2000 package (Otwinowski & Minor, 1997).
2.3. Molecular replacement
The Matthews coefficient (Matthews, 1968) was calculated using
14 894 kDa as the molecular weight. The region Val365–Gly484 of
yeast PDI (PDB code 2b5e), which shares 28% identity with
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Q4DV70, was selected as a search model for the molecular-replace-
ment phasing method. The model was modified using the ‘last
common atom’ option of the CHAINSAW software (Stein, 2008)
available in the CCP4 package and nonprotein atoms were removed
from the coordinate file. Molecular replacement was carried out using
the MOLREP software (Vagin & Teplyakov, 1997) from CCP4.
Model refinement was carried out by simulated annealing using CNS
(Brünger et al., 1998) followed by cycles of manual inspection and
model building with Coot (Emsley & Cowtan, 2004) and restrained
refinement with REFMAC (Murshudov et al., 1997).
3. Results and discussion
The recombinant Q4DV70 protein was purified from E. coli extracts
by IMAC (Fig. 1). The His tag was cleaved with TEV protease,
leaving a GHM tripeptide at the N-terminus of the protein. Aggre-
gated proteins were removed by gel filtration. A second IMAC was
carried out to adsorb the His-tagged TEV protease and the residual
undigested His-tagged Q4DV70 from cleaved Q4DV70; the purified
Q4DV70 without a His tag was used for crystallization. Crystals of Q4DV70 grew as a cluster of plates in 20% PEG 3350, 200 mM
sodium thiocyanate pH 6.9 from JCSG (Page et al., 2003) in 1 d at
291 K. Variations of this initial condition and the use of additives did
not change the shape of the crystals (Fig. 2). One plate was broken
apart from a cluster (grown in 25% PEG 1500, 200 mM sodium
thiocyanate pH 6.9, 10 mM phenol) and placed directly into a 100 K
nitrogen-gas stream. As it diffracted very well despite the formation
of ice over the crystal, a data set was collected (Table 1). The crystal
belonged to space group P212121, with unit-cell parameters a = 35.04,
b = 50.76, c = 60.98 Å. Unfortunately, the ice formation affected the
completeness. The calculated Matthews coefficient was 1.82 Å3 Da1,
which corresponds to one molecule per asymmetric unit and 32.5%
solvent content. Molecular replacement carried out using the region
Val365–Gly484 of yeast PDI resulted in a translation-function
contrast of 4.2. After a few cycles of refinement, 90% of the chain was
constructed. A second data set was collected from a crystal grown in
25% PEG 1500, 200 mM sodium thiocyanate pH 6.9, 10 mM phenol,
10%(v/v) ethylene glycol. This crystal also belonged to space group
P212121, with a small variation in the unit-cell parameters. This data
set is being used for the refinement of the model constructed with the
first data set, preserving the same set of reflections used for the
calculation of Rfree.
Once the structure of Q4DV70 from T. cruzi has been refined, it
will be compared with other thioredoxin-like structures, especially
those lacking catalytic cysteines, in order to obtain functional infor-
mation. The hypothesis that this protein might act as a chaperone and
the fact that its expression profile changes during metacyclogenesis
builds an interesting case for the biology of this human pathogen.
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Figure 1
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Figure 2
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of 5  50  500 mm.
Table 1
Data-collection and processing statistics for Q4DV70 crystals.
Values in parentheses are for the highest resolution shell.
Crystal Not cryoprotected Cryoprotected
Wavelength (Å) 1.459 1.459
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